BRIEF-Esperion Reports $156 To $160 Million In Preliminary Full-Year 2025 U.S. Net Product Sales
Reuters
Jan 12
BRIEF-Esperion Reports $156 To $160 Million In Preliminary Full-Year 2025 U.S. Net Product Sales
Jan 11 (Reuters) - Esperion Therapeutics Inc ESPR.O:
ESPERION PROVIDES BUSINESS UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
ESPERION THERAPEUTICS INC - REPORTS $156 TO $160 MILLION IN PRELIMINARY* FULL-YEAR 2025 U.S. NET PRODUCT SALES
Source text: ID:nGNX23vRHk
Further company coverage: ESPR.O
((Reuters.briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.